THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

Amgen announced the launch of AmgenNow, a new direct-to-patient programme starting with Repatha (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of ...

Patients receiving Repatha achieved a median LDL cholesterol level of 45 mg/dL compared to 109 mg/dL in the placebo group. "Repatha has once again demonstrated its ability to protect patients from the ...

THOUSAND OAKS, Calif. - The U.S. Food and Drug Administration has broadened the approved use of Amgen’s (NASDAQ:AMGN) Repatha to include adults at increased risk for major adverse cardiovascular ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...